168 related articles for article (PubMed ID: 26910128)
1. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?
Beall RF; Nickerson JW; Kaplan WA; Attaran A
PLoS One; 2016; 11(2):e0148939. PubMed ID: 26910128
[TBL] [Abstract][Full Text] [Related]
2. Patenting Strategies on Inhaler Delivery Devices.
Demkowicz BJ; Tu SS; Kesselheim AS; Carrier MA; Feldman WB
Chest; 2023 Aug; 164(2):450-460. PubMed ID: 36842533
[TBL] [Abstract][Full Text] [Related]
3. Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
Olsen A; Beall RF; Knox RP; Tu SS; Kesselheim AS; Feldman WB
PLoS Med; 2023 Nov; 20(11):e1004309. PubMed ID: 37971985
[TBL] [Abstract][Full Text] [Related]
4. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
Alhiary R; Kesselheim AS; Gabriele S; Beall RF; Tu SS; Feldman WB
JAMA; 2023 Aug; 330(7):650-657. PubMed ID: 37505513
[TBL] [Abstract][Full Text] [Related]
5. Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.
Feldman WB; Bloomfield D; Beall RF; Kesselheim AS
Health Aff (Millwood); 2022 Jun; 41(6):787-796. PubMed ID: 35579925
[TBL] [Abstract][Full Text] [Related]
6. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
7. Patent "Evergreening" of Medicine-Device Combination Products: A Global Perspective.
Beall RF; Glazer T; Ahmad H; Buell M; Hahn S; Houston AR; Kesselheim AS; Nickerson JW; Kaplan W
Healthc Policy; 2022 Oct; 18(2):14-26. PubMed ID: 36495532
[TBL] [Abstract][Full Text] [Related]
8. Are patents impeding medical care and innovation?
Gold ER; Kaplan W; Orbinski J; Harland-Logan S; N-Marandi S
PLoS Med; 2010 Jan; 7(1):e1000208. PubMed ID: 20052274
[TBL] [Abstract][Full Text] [Related]
9. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.
Darrow JJ; Beall RF; Kesselheim AS
Appl Health Econ Health Policy; 2019 Feb; 17(1):47-54. PubMed ID: 30141133
[TBL] [Abstract][Full Text] [Related]
10. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
Tang WL
Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
[TBL] [Abstract][Full Text] [Related]
11. Swimming upstream: developing and commercializing diabetes products in a patent protected world.
Hopkins BP; Miller KJ
J Diabetes Sci Technol; 2013 Mar; 7(2):302-7. PubMed ID: 23566985
[TBL] [Abstract][Full Text] [Related]
12. The global intellectual property ecosystem for insulin and its public health implications: an observational study.
Kaplan WA; Beall RF
J Pharm Policy Pract; 2017; 10():3. PubMed ID: 27446593
[TBL] [Abstract][Full Text] [Related]
13. Could patents interfere with the development of a cardiovascular polypill?
Beall RF; Schwalm JD; Huffman MD; McCready T; Yusuf S; Attaran A
J Transl Med; 2016 Aug; 14(1):242. PubMed ID: 27538505
[TBL] [Abstract][Full Text] [Related]
14. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
15. Herbal drug patenting in India: IP potential.
Sahoo N; Manchikanti P; Dey SH
J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
[TBL] [Abstract][Full Text] [Related]
16. Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic.
Bacigalupo ML; Pignataro MF; Scopel CT; Kondratyuk S; Mellouk O; Chaves GC
Front Med (Lausanne); 2023; 10():1287542. PubMed ID: 38126073
[TBL] [Abstract][Full Text] [Related]
17. Evergreened drugs or evergreened profits?
Siddalingaiah S; Fugh-Berman A
J Eval Clin Pract; 2022 Dec; 28(6):1119-1126. PubMed ID: 35543377
[TBL] [Abstract][Full Text] [Related]
18. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
19. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.
Kesselheim AS
AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832
[TBL] [Abstract][Full Text] [Related]
20. India: Court upholds patent law denying patents for slightly modified versions of existing drugs.
Swamy M
HIV AIDS Policy Law Rev; 2007 Dec; 12(2-3):50-1. PubMed ID: 18459215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
